[The parameters of clearance of industrially significant alpha-emitters from the lungs of mammals].
Results of assessment of biokinetic parameters of change in the burden of significant alpha-emitters in the lungs of mammals in various times after inhalation intake (Qt(lung)) were generalized. 1740 Wistar rats of both sex with the initial age of 2-2.5 months and 143 mature mongrel dogs used in 23 and 3 animal tests, respectively, were involved in this work. The analysis of experimental data resulted in selection of three groups of chemically soluble compounds of alpha-emitters that differ in the rate of radionuclide clearance from the lung as well as in integral doses. Stable complex compounds of quadrivalent and of hexavalent nuclides and non-complex salts of quinquivalent and of hexavalent 237Np were assigned to the group of soluble compounds of 239Pu and 237Np. A three-component exponential model of change in Qt(lung) with the prevalence of fast and of intermediate phases (55%, T(eff) = 0.41 days and 35%, T(eff) = 18.1 days respectively) and the presence of a slow clearance phase (10%, T(eff) = 206 days) was developed for these compounds. Complex compounds of quadrivalent 239Pu and 237Np unstable in the environment of pH and of body temperature, their non-complex salts of mineral acids in ionic or polymer form, and submicron plutonium dioxide (SMD = 0.07 mkm) were assigned to the group of relatively soluble compounds includes. An exponential model with 2-3 components with the prevalence of intermediate and of slow clearance phases (71%, T(eff) = 19.3 days and 22%, T(eff) = 169 days respectively) was developed for compounds of this group. The third group of the compounds is presented based on the soluble 241Am compounds that could be typical for stable trivalent compounds of rare-earth and transuranium radionuclides. Their biokinetics is described by a 3-4-component exponential model with the fast phase prevailing (96.7%, T(eff) < or = 6.8 days), and with intermediate (2.6%, T(eff) = 69 days) and with slow (0.7%, T(eff) = 1040 days) phases being negligible. Physical chemicas and biological processes determining nuclides biokinetics in lungs are discussed.
E P
EP
Liubchanskiĭ
O V
OV
Kuz'menko
S N
SN
Sokolova
D008671:Actinoid Series Elements / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000336:Aerosols; D000512:Alpha Particles; D000818:Animals; D001822:Body Burden; D005260:Female; D019570:Inhalation Exposure; D008168:Lung / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate; D051381:Rats; D017208:Rats, Wistar
D008671:Actinoid Series Elements; D000336:Aerosols